405 related articles for article (PubMed ID: 22349515)
1. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells in malignant melanoma.
Umansky V; Sevko A; Gebhardt C; Utikal J
J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
[TBL] [Abstract][Full Text] [Related]
3. New insights into chronic inflammation-induced immunosuppression.
Kanterman J; Sade-Feldman M; Baniyash M
Semin Cancer Biol; 2012 Aug; 22(4):307-18. PubMed ID: 22387003
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
5. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
[TBL] [Abstract][Full Text] [Related]
7. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
[TBL] [Abstract][Full Text] [Related]
9. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
10. Introduction to the role of the immune system in melanoma.
Margolin K
Hematol Oncol Clin North Am; 2014 Jun; 28(3):537-58. PubMed ID: 24880946
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
Sevko A; Michels T; Vrohlings M; Umansky L; Beckhove P; Kato M; Shurin GV; Shurin MR; Umansky V
J Immunol; 2013 Mar; 190(5):2464-71. PubMed ID: 23359505
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression associated with chronic inflammation in the tumor microenvironment.
Wang D; DuBois RN
Carcinogenesis; 2015 Oct; 36(10):1085-93. PubMed ID: 26354776
[TBL] [Abstract][Full Text] [Related]
13. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?
Auphan-Anezin N; Verdeil G; Grange M; Soudja SM; Wehbe M; Buferne M; Mas A; Schmitt-Verhulst AM
Pigment Cell Melanoma Res; 2013 Mar; 26(2):167-75. PubMed ID: 23217139
[TBL] [Abstract][Full Text] [Related]
17. Myeloid regulatory cells in tumor spreading and metastasis.
Keskinov AA; Shurin MR
Immunobiology; 2015 Feb; 220(2):236-42. PubMed ID: 25178934
[TBL] [Abstract][Full Text] [Related]
18. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
19. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
Umansky V; Blattner C; Gebhardt C; Utikal J
Cancer Immunol Immunother; 2017 Aug; 66(8):1015-1023. PubMed ID: 28382399
[TBL] [Abstract][Full Text] [Related]
20. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2326s-2330s. PubMed ID: 16609053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
